Two novel LHX3 mutations in patients with combined pituitary hormone deficiency including cervical rigidity and sensorineural hearing loss

Khushnooda Ramzan¹*, Bassam Bin-Abbas², Lolwa Al-Jomaa¹, Rabab Allam¹, Mohammed Al-Owain³,⁴† and Faiqa Imtiaz¹†

Abstract

Background: Congenital combined pituitary hormone deficiency (CPHD) is a rare heterogeneous group of conditions. CPHD-type 3 (CPHD3; MIM# 221750) is caused by recessive mutations in LHX3, a LIM-homeodomain transcription factor gene. The isoforms of LHX3 are critical for pituitary gland formation and specification of the anterior pituitary hormone-secreting cell types. They also play distinct roles in the development of neuroendocrine and auditory systems.

Case presentation: Here, we summarize the clinical, endocrinological, radiological and molecular features of three patients from two unrelated families. Clinical evaluation revealed severe CPHD coupled with cervical vertebral malformations (rigid neck, scoliosis), mild developmental delay and moderate sensorineural hearing loss (SNHL). The patients were diagnosed with CPHD3 based on the array of hormone deficiencies and other associated syndromic symptoms, suggestive of targeted LHX3 gene sequencing. A novel missense mutation c.437G > T (p. Cys146Phe) and a novel nonsense mutation c.466C > T (p. Arg156Ter), both in homozygous forms, were found. The altered Cys146 resides in the LIM2 domain of the encoded protein and is a phylogenetically conserved residue, which mediates LHX3 transcription factor binding with a zinc cation. The p. Arg156Ter is predicted to result in a severely truncated protein, lacking the DNA binding homeodomain.

Conclusions: Considering genotype/phenotype correlation, we suggest that the presence of SNHL and limited neck rotation should be considered in the differential diagnosis of CPHD3 to facilitate molecular diagnosis. This report describes the first LHX3 mutations from Saudi patients and highlights the importance of combining molecular diagnosis with the clinical findings. In addition, it also expands the knowledge of LHX3-related CPHD3 phenotype and the allelic spectrum for this gene.

Keywords: LHX3, Pituitary hormone deficiency, Sensorineural hearing loss, Cysteine 146, Differential diagnosis

Background

Combined pituitary hormone deficiency (CPHD) refers to a rare heterogeneous group of conditions, which is characterized by true deficiency of at least two anterior pituitary hormones. CPHD has been linked with abnormalities in the genes encoding both signaling molecules and transcription factors, which have been shown to play a role in the development and maturation of the pituitary gland. These genes include HESX1, LHX3, LHX4, POLUIF1, PROPI, SIX6, OTX2, PTX2, GLI2 and SOX3 [1–3]. The pituitary phenotype caused by genetic defects in these genes may be isolated (pure pituitary phenotype) or may be associated with variable extrapituitary manifestations (syndromic CPHD) [4]. Clinical presentation is variable, depending on the type and severity of deficiencies and at the age of diagnosis. If untreated, main symptoms usually include short stature, cognitive alterations or delayed puberty. CPHD is related to significant morbidity, especially hypoglycemia and its consequences in newborns. Treatment should be started...
immediately and a strict specialized follow-up is necessary [5]. Here, we describe the clinical, endocrinological, radiological and molecular features of three new cases of \textit{LHX3}-related CPHD3.

Mutations in the \textit{LHX3} gene (MIM# 600577), located on chromosome 9q34.3, underlie combined pituitary hormone deficiency type 3 (CPHD3, MIM# 221750). The encoded protein (Uniprot: Q9UBR4) is a LIM-homeodomain (LIM-HD) transcription factor, which features two amino-terminal LIM domains (cysteine-rich zinc-binding domain) and a centrally-located DNA-binding homeodomain [6]. In addition, the \textit{LHX3} protein also possesses a carboxyl terminus that includes the major trans-activation domain. Alternative splicing generates two isoforms, \textit{LHX3a} and \textit{LHX3b}, which are 397 and 402 amino acids long, respectively. These isoforms possess identical LIM domains, homeodomains and carboxyl termini but possess different amino-termini and differentially activate pituitary gene targets [7, 8].

Typically, genetically-confirmed CPHD3 patients with homozygous \textit{LHX3} mutations present with hypopituitarism including deficiencies in the growth hormone (GH), thyroid stimulating hormone (TSH), prolactin (PRL), leutinizing hormone (LH), follicular stimulating hormone (FSH) and abnormal pituitary morphology. Adrenocorticotrophic hormone (ACTH) deficiency, cervical abnormalities with or without restricted neck rotation and sensorineural hearing loss (SNHL) has also been reported in a subset of these patients. The phenotypes in three patients (aged 2–11 year) in this report include CPHD, rigid cervical spine, restricted neck rotation, scoliosis, mild developmental delay and congenital hearing impairment. Targeted sequencing of the \textit{LHX3} gene revealed two novel recessive variants in these patients. Finally, we surveyed the functional consequences of these mutations.

\textbf{Case presentation}

We ascertained three patients with syndromic symptoms associated with CPHD. An informed written consent was used to recruit the patients and their family members. All affected patients underwent detailed examination at the departments of clinical genetics and pediatrics of King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Laboratory testing, radiological investigation (X-ray) and audiologic assessments were performed. Pituitary examination was made by multisequential multplanar magnetic resonance imaging (MRI) by applying standard scanning protocols [9]. The hormonal tests were measured by radioimmunoassay techniques by Roche Diagnostics, USA. Hormonal evaluation included basal levels for GH response to glucagon stimulation, TSH, PRL, LH, FSH, cortisol, ACTH and free thyroxine (FT4) levels. Growth biochemical markers including insulin growth factor 1 (IGF1) and insulin growth factor binding protein 3 (IGFBP3) were also assessed. The diagnoses of hormonal deficiencies were established using the normal range as cutoff limits: Basal GH (>10 μg/L), TSH (0.27–4.2 mU/L), PRL (2.5–15 μg/L), LH (0.1–3.3 U/L), FSH (0.1–7 U/L), ACTH (5–60 ng/L), cortisol (190–750 nmol/L), FT4 (12–22 pmol/L), IGF1 (115–498 ng/L) and IGFBP3 (0.7–3.6 mg/L).

\textbf{Cases}

\textbf{Patient 1, Family 1}

This boy (II:2, Fig. 1a) was a product of an uneventful pregnancy and normal vaginal delivery at 39 weeks of gestation, whose healthy consanguineous parents had previously lost a daughter in infancy probably because of the same condition. At birth, he was noted to have a microopenis with a stretched penile length of 1.8 cm and undescended testes. Other dysmorphic features included short webbed neck with limited rotation and triangular face. During hypoglycemic attack at the 3rd month of the life, ACTH and GH deficiencies were diagnosed. Later TSH and gonadotropin deficiencies were also found (see Table 1). Both TSH and FT4 were low suggesting central hypothyroidism. MRI of pituitary gland showed a small cystic lesion replacing the adenohypophysis of the pituitary gland representing developmental cystic abnormality. The pituitary stalk was present with normally placed neurohypophysis. Skeletal survey showed closure of sagittal suture causing dolichocephaly and hypoplasia of the facial bones. Thyroxine (25 μg daily), hydrocortisone (2.5 mg twice daily) and subcutaneous injections for GH (0.035 mg/kg/day) were initiated to normalize glycemia and to improve somatic growth at the 5th month of age. His height was 107 cm at age of 7 years (on the 5th percentile, −2SD). Testosterone therapy was given at a dose of 25 mg monthly for 3 months, which improved penile length to 3.1 cm. He also had moderate SNHL of the age of 2 years.

\textbf{Patient 2, Family 2}

The proband (II:2, Fig. 1b) of family 2 is the second child of healthy first degree parents, born via normal vaginal delivery at 39 weeks of gestation. He was initially evaluated in a local hospital for mild hypoglycemic attacks which were associated with jitteriness and irritability. He was first seen at our clinic at age of 2 years. He was clinically normal, apart from an abnormal head tilt secondary to abnormal neck posturing. His height was -3SD and he had a stretched penile length of 0.5 cm (−5.3 SD) with non-palpable testes. The patient had craniosynostosis causing plagiocephaly. Hypopituitarism was confirmed (Table 1). An MRI of his pituitary gland showed a small rudimentary adenohypophysis and a normal pituitary stalk present with normally placed neurohypophysis. A skeletal survey showed closure of sagittal
suture causing dolichocephaly and thoracic scoliosis. L-thyroxine (50 mcg daily), hydrocortisone (2.5 mg twice daily) and GH injections (0.035 mg/kg/day) were initiated. Orchipexy was performed at the age of 2.5 years. Testosterone therapy (25 mg monthly) was given for 3 months which improved penile length to 1.5 cm. Two other testosterone courses were given at the age of 5 years and 10 years with a partial improvement in penile length to 3 cm. Bilateral moderate SNHL was also found at the age of 3 years. His growth improved in response to GH

Fig. 1 Family pedigrees, genotypes, growth charts for patients and clinical presentation. **a, b** Pedigrees of the families studied with CPHD3 demonstrating the recessive inheritance pattern. Filled symbols indicate affected individuals. The respective genotype is indicated below each individual. Symbols are: + for wild type allele; − for mutated allele. **c, d, e** Representative growth chart for Patients II:2 (Family 1), II:2 (Family 2) and II:4 (Family 2) showing reduced growth velocity for all patients and reduced response for patient 2 and 3 compared to patient 1. Affected patient 2 (II:2 from family 2) showing **f** neck rotation, **g** scoliosis and **h** lower thoracic scoliosis by spine x-ray. **i, j** Multisequential multiplanar brain MRI reveals pituitary gland hypoplasia for patient II:2 from family 1 **i** coronal view **j** sagittal view. **k** Skull x-ray demonstrates an increased anterior-posterior diameter of calvarium suggestive of dolichocephaly.
treatment; he had a growth velocity of 3–4 cm per year. His height was 110 cm at the age of 10 years (−4SD). The prescribed dose for GH injections was 0.035 mg/kg/day; however the patient was not compliant with treatment, which negatively affected the growth velocity and the ultimate height at the age of 10 years.

**Patient 3, Family 2**
The younger sister (II:4, Fig. 1b) of the patient 2 was born via normal vaginal delivery at 39 weeks of gestation. Her birth weight (2.9 kg) and birth length (46 cm) was adequate for gestational age. She also presented with jitteriness secondary to hypoglycemia at 2nd month of age and was suspected to have hypopituitarism (Table 1), because her older brother had been diagnosed with the same condition before. Treatment thyroxine, hydrocortisone and GH injections were started. She has moderate SNHL and a normal skeletal survey. Magnetic resonance imaging showed a normal pituitary gland. Clinical features and hormonal levels for all three affected patients are summarized in Table 1.

**Genetic analyses**
Genomic DNA extraction was carried out using PURE-GENE DNA Extraction Kit according to manufacturer’s instructions (Gentra Systems, Minneapolis, MN) from

| Table 1 | Clinical data for three patients with novel **LHX3** mutations |
|---------|-------------------------------------------------------------|
|         | Patient 1 (II:2, Family 1) | Patient 2 (II:2, Family 2) | Patient 3 (II:4, Family 2) |
| Age, years | 7                        | 11                       | 2                             |
| Gestational age, weeks | 39                       | 39                       | 39                            |
| Birth weight, kg (SD) | 3.2 (0.5SD)               | 3.2 (−0.7SD)              | 2.9 (−0.7SD)                  |
| Birth length, cm (SD) | 45 (−2.5SD)               | NA                       | 46 (−1.8SD)                   |
| Age of onset, months | 3                        | 2                        | 2                             |
| Initial manifestation hypopituitarism | +                       | +                        | +                             |
| Basal GH μg/L (>10) | <0.2                     | <0.5                     | <0.5                          |
| TSH mU/L (0.27–4.2) | 0.02                     | 0.04                     | 0.4                           |
| PRL μg/L (2.5–15) | 0.1                      | 0.1                      | NA                            |
| LH U/L (0.1–3.3) | <0.1                     | <0.1                     | <0.1                          |
| FSH U/L (0.1–7) | <0.1                     | <0.1                     | <0.1                          |
| ACTH ng/L (5–60) | 6                        | 8                        | 16                            |
| cortisol nmol/L (190–750) | 70                      | 62                       | 102                           |
| FT4 pmol/L (12–22) | 4.4                      | 9.3                      | 10.3                          |
| IGF1 ng/L (115–498) | <25                      | <25                      | NA                            |
| IGFBP3 mg/L (0.7–3.6) | <0.5                    | <0.3                     | NA                            |
| Hypoplastic pituitary gland | +                       | +                        | -                             |
| Limited neck rotation | +                        | +                        | -                             |
| SNHL | +                        | +                        | +                             |
| Developmental delay (Mild) | +                       | +                        | +                             |
| Other findings | Dolichocephaly, Hypoplasia of facial bones, frontal bossing, short webbed neck | Dolichocephaly, Thoracic scoliosis, squint | None |
| Mutation Identified | c.437G>T (p. Cys146Phe) Homozygous | c.466C>T (p. Arg156Ter) Homozygous | |
| Type of mutation | Missense mutation | Nonsense | |
| Effect on protein | Location a well-established domain | Null mutation | |
| Computation (in silico) predictive analysis | "Damaging" | "Damaging" | |
| Population data | Not annotated as polymorphism | Not annotated as polymorphism | |
| Functional data | Located in functional domain | Located in functional domain | |
| Allelic and family segregation data | Recessive mutation and strong segregation | Recessive mutation and strong segregation | |
| Other Evidence | Relevant to patient’s phenotype | Relevant to patient’s phenotype | |
| Variant classification (ACMG) | Likely pathogenic | Pathogenic | |

NA not available
the venous blood samples collected from each subject. All exons and adjacent exon-intron boundaries of the both LHX3 transcripts were amplified in Veriti™ 96-Well Fast Thermal Cycler (Applied Biosystems, Foster City, CA) using HotStar Taq DNA Polymerase (Qiagen, Germantown, MD). Primers were designed by the use of Primer3 web based server (http://frodo.wi.mit.edu/primer3/; sequences of primers used for PCR amplification are listed in Table 2). The PCR products were sequenced by dye termination sequencing using BigDye® Terminator Cycle Sequencing v3.1 Kit and ABI Prism 3730 Genetic Analyzer (Applied Biosystems, Inc., Foster City, CA, USA). Sequence analysis was performed using the SeqMan 6.1 module of the Lasergene (DNA Star Inc. WI, USA) software package and the results were compared with reference sequence. Accession numbers: Nucleotide and amino acid numbering are for LHX3, variant 2 (also known as isoform b) and correspond to NCBI reference sequence accession number NM_014564.3 for the cDNA and NP_055379.1 for the protein.

In silico prediction and pathogenicity assessment

For interpretation of the identified sequence variants as per ACMG guidelines, PolyPhen2 (Polymorphism phenotyping: http://genetics.bwh.harvard.edu/pph2/), SIFT (Sorting Intolerant From Tolerant; http://sift.jcvi.org/) and MutationTaster (http://www.mutationtaster.org/) were used for pathogenicity assessment [10]. Project HOPE ([11]; http://www.cmbi.ru.nl/hope/) was used to predict the possible structural changes in the mutant protein using a normal LHX3 structure (PDB-file: 2JTN). The sequences form the Homo Sapiens LHX3 protein and homologous proteins from other eukaryotic species were obtained from the National Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/). A multiple alignment between these proteins was performed using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/).

**Results**

Sanger sequencing of LHX3 gene in the affected boy (II:2 from pedigree, Fig. 1a) from the first consanguineous family led us to the identification of a homozygous nucleotide change (c.437G > T), resulting in a cysteine-to-phenylalanine substitution at 146 amino acid of the encoded protein (p. Cys146Phe) (Fig. 2a). In the two sibs (II:2 & II:4 from pedigree, Fig. 1b) from the second family, we identified homozygosity for a single base exchange (c.466C > T). At the protein level, this transition predicts change of amino acid 156 from arginine to a stop codon (p. Arg156Ter) (Fig. 2b). Parents and siblings of the affected patients were all healthy and show no signs or symptoms related to the disorder. In addition, they were either heterozygous or wild type for the identified mutations (Fig. 1a and b). p. Cys146Phe is predicted to be "damaging" based on PolyPhen2, SIFT and MutationTaster. p. Arg156Ter is also predicted to be "disease causing" by MutationTaster. Both the alterations were not annotated in either dbSNP [12], the 1000 Genomes Project database [13], or Exome Aggregation Consortium (ExAC) [14] and were absent in 400 normal chromosomes of ethnically matched controls, precluding that these represented benign or more common polymorphisms.

The identified p. Cys146Phe substitution resides in the LIM2 domain of the LHX3 protein (Q9UBR4). LIM domain is recognized as a tandem zinc-finger (Znf) structure that functions as a modular protein-binding interface and LIM homeodomain proteins have been shown to play roles in cytoskeletal organization, organ development, cell adhesion, cell motility and signal transduction [15, 16]. Znf motif mostly contain a pattern of cysteine and histidine residues that coordinately bind to zinc ions at the base of each of the two 'fingers', but in some cases they bind other metals such as iron, or no metal at all [17]. The cysteine at position 146 is a zinc ligating residue, involved in binding with the zinc cation (Fig. 2c). A three-dimensional-structure prediction analysis for p. Cys146Phe mutation by project HOPE predicts that the mutant residue (phenylalanine) will probably not fit in place of the smaller size wild-type cysteine residue which is buried in the core of the protein and will thus disturb the possible rearrangements of surrounding residues. In addition, the replacement of cysteine at p.146 will disrupt the putative interaction with zinc cation, thus affecting biological activity of LHX3. This cysteine is entirely conserved in LHX3.

| Primer   | Sense Strand          | Antisense Strand          |
|----------|-----------------------|---------------------------|
| LHX3_Exon 1a | 5'- CAACCCAGCCAGGGAG - 3'  | 5'- GTTCCATCTCTGTGTCCCG - 3'  |
| LHX3_ Exon 1b | 5'- CCGGAGTCGGTGCGGAC - 3'  | 5'- GCCAGATCTCTAGCTCC - 3'  |
| LHX3_ Exon 2 | 5'- CAGCCCTGAGCTCTGTTG - 3'  | 5'- TGAATGGAGGGGAGAGGT - 3'  |
| LHX3_ Exon 3 | 5'- CGGACAGAGCCCTCCTC - 3'  | 5'- GGAGGAGATTGGGCGGAC - 3'  |
| LHX3_ Exon 4 + 5 | 5'- CTTCCCGAGAAGGCTTG - 3'  | 5'- TCCATGGGAAATCTAGAC - 3'  |
| LHX3_ Exon 6 | 5'- CTGCCAGGATGGGACCTG - 3'  | 5'- CACCAGCCCTCCCTGTGAC - 3'  |
Identification of two novel mutations in LHX3. a) Sequencing chromatogram indicating the homozygous wild type, heterozygous carrier and homozygous mutant forms. Homozygous c.437 G > T (p. Cys146Phe) mutation is identified in affected individual (II:2, family 1). b) Homozygous c.466 C > T (p. Arg156Ter) mutation is identified in affected individuals (II:2 & II:4, family 2). Nucleotides and amino acid numbering correspond to NM_014564.3 for the cDNA and NP_055379.1 for the protein. Nucleotides were numbered using A of the ATG translation initiation codon as +1 nucleotide of the coding sequence. Mutations are highlighted (arrow). c) Ribbon/Cartoon-presentation of zinc finger motif of the LHX3 consisting of α-helix (green) and β-sheets (brown). The Zn binding residues of LIM domains are highly conserved; cysteine at position 146 (yellow) is a zinc ligating residue, involved in binding with the zinc cation (brown). d) The multiple-sequence alignment was generated with the Clustal Omega Multiple Sequence Alignment tool and depicts conservation of the crucial p. Cys146 residue during evolution. Asterisk (*) indicates positions which have a single, fully conserved residue. Colon (:) indicates conservation between groups of strongly similar properties - scoring > 0.5. e) LHX3 mutations associated with combined pituitary hormone deficiency. Schematic representation of intron-exon structure of LHX3 gene, domain graph of the encoded protein (Uniprot identifier: Q9UBR4), and the genetic variants. Exons are designated as boxes 1–6 and introns are shown by thin lines. A full-length wild type LHX3 protein is shown, with its N-terminus and C-terminus. Alternative splicing generates two isoforms, LHX3a and LHX3b, which are 397 and 402 amino acids long respectively. The isoforms differ only in the amino-terminal domains. Other known functional domains are following: LIM domains (LIM); homeodomain (HD), and carboxyl trans-activation domain (LSD). Novel variants identified in our study are boxed in red alongside previously reported variants in HGMD database [28]. The mutations are grouped according to canonical classes and further identified by their amino acid changes.
proteins in homologous sequences (Fig. 2d). It is part of the amino acid sequence ‘signature’ that defines the LIM domains proteins [18], indicating that the Cys146 residue is critical to overall LHX3 function. The identified nonsense mutation p. Arg156Ter is predicted to result in a premature stop codon, loss of entire DNA-binding homeodomain and carboxyl terminus causing the production of short, inactive LHX3 protein or non-sense mediated decay of the aberrant mRNA. Mutant LHX3 proteins lacking a homeodomain do not bind DNA and thus do not induce transcription from pituitary genes. A complete loss of function is assumed with this homozygous mutation.

Hence, the factors that p. Arg156Ter being a null variant and critical location of p. Cys146Phe in a well-established domain, their absence in population data/controls, computational evidence, segregation analysis and relevance to the patients phenotype, led us to classify these allelic variants; p. Arg156Ter and p. Cys146Phe as “pathogenic” and “likely pathogenic” respectively, according to the recommendations of ACMG guidelines [10] for the interpretation of sequence variants (see Table 1).

Discussion and conclusions

Pituitary organogenesis is a highly complex process and tightly regulated cascade of several transcription activators and repressors, and signaling molecules [19, 20]. Anterior pituitary ontogenesis begins early around embryonic day (E) 7.5, corresponding to the first visualization of the pituitary placode. Briefly, during the early stage of pituitary development, which corresponds to E6.5-10.5 in mice, the extrinsic signaling pathways are activated, including bone morphogenetic protein (BMP2, BMP4), fibroblast growth factor (FGF8, 10 and 18), Sonic Hedgehog (SHH) and wingless (WNT4) pathways [21]. Within the developing Rathke’s pouch and anterior pituitary, a number of transcription factors are involved in a timely manner during the steps of differentiation; early acting such as paired homeodomain transcription factors (HESX1, PITX1, PITX2), LIM homeobox (LHX3, LHX4) or late-acting such as PROP1 (prophet of Pit-1) and POU1F1 (previously called PIT-1) [22]. Lhx3 gene expression is detected in the developing nervous system and Rathke’s pouch at approximately E9 [6]. By E12, POU1F1 synergistically partners with PITX1 and PITX2 for the differentiation of specific pituitary-specific cell types; thyrotropes, lactotropes and somatotropes [23]. The gonadotrope and thyrotropic precursors are activated by zinc-finger transcription factor, GATA2 in response to inductive interaction of LHX3 and BMP2 signaling [20]. Terminal differentiation of the pituitary completes at approximately E17 in response to the tightly controlled temporospatial gradient expression of transcription factor [7, 24]. A simplified scheme of expression of the transcription factors is given in Fig. 3. In Lhx3 null mutant mice, Rathke’s pouch is initially formed but then fails to grow resulting in either stillbirth or death shortly following birth, thus providing a genetic paradigm for the study of pituitary development [25]. LHX3 is known to plays an essential role in the proper development of the spinal motoneurons (which likely explains neck rotation anomalies in human with LHX3 mutation) and is also expressed in the auditory system [4, 26, 27]. Only a small number of studies have previously reported the clinical phenotype and genetic basis of LHX3 patients (Human Gene Mutation Database

**Fig. 3** A simplified scheme of the development cascade representing the main transcription factors expression during pituitary development (adapted from de Moraes et al. [20]). Pituitary cell lineages are determined by the activation or repression of each transcription factor. LHX3 participates in the pituitary cell differentiation and maturation process. The anterior pituitary consists of five distinct cell types. These cells and their specific hormones are lactotropes, which produce PRL; somatotropes, which produce GH; gonadotropes, which produce LH and FSH; corticotropes, which produce ACTH; and thyrotropes, which produce TSH. Any mutation that alters the length, quality or quantity of any gene involved in the development cascade will result in pituitary development failure.
Together with two novel mutations identified in our study, there are now 16 different \( LHX3 \) variants (Fig. 2e) in patients with CPHD3 phenotype as detailed in Table 3. The clinical phenotypes of human \( LHX3 \) mutations encompass a varied presentation. The earliest descriptions of \( LHX3 \) mutations were associated with panhypopituitarism without ACTH deficiency or any extrapituitary phenotypes [29]. Later, a rigid cervical spine with limited head rotation, mental retardation and MRI findings of a hypodense lesion in the pituitary was also reported in addition to CPHD [30]. Four homozygous \( LHX3 \) mutations with CPHD, with or without limited neck rotation were identified in a cohort of 366 patients with hypopituitarism or CPHD. Hearing status in these patients was not documented to be either normal or with any hearing deficit [31]. Bilateral SNHL was first associated as an additional CPHD3 phenotype in the four patients with CPHD, severe pituitary hypoplasia, ACTH deficiency and skeletal abnormalities [32]. The occurrence of SNHL was explained by expression of \( LHX3 \) in a pattern overlapping that of \( SOX2 \) in the sensory epithelium of developing inner ear [32]. Later, six patients from the same genealogy with CPHD, restricted neck rotation, scoliosis and congenital hearing impairment were described to harbor a recessive novel splice acceptor site mutation [33]. More recently, a complete loss of function mutation is associated with CPHD including ACTH deficiency, short neck and SNHL [5]. Compound heterozygous \( LHX3 \) defects in a nonconsanguineous patient with syndromic CPHD, severe scoliosis and normal intelligence and a novel homozygous mutation p.T194R were recently reported [34, 35].

A candidate-gene approach was used on the basis of documented pituitary abnormalities, restricted neck rotation and SNHL, \( LHX3 \) gene was then sequenced. Herein, we characterize two novel mutations in three patients from two unrelated Saudi consanguineous families. The three patients presented with early infantile hypoglycemia and deficiency of all anterior pituitary hormones including ACTH. Two of the affected patients also displayed rigidity of the cervical spine and short neck with limited rotation. Clinically, there was no evidence of cardiac defects or skin manifestations as reported earlier in some reports [32, 34]. Birth length in one of our patients was slightly below the mean centile for gestational age, which supports earlier findings that IGFs are necessary for that period but the severe deficiency interacts with intrauterine longitudinal growth [33]. Hearing impairment was noticed for all three affected at the age of 2–3 years, audiologic assessment later confirmed moderate SNHL that was partially managed with hearing aids and all had receptive and expressive language delay. Perinatal mortality has been reported in other families with \( LHX3 \) mutations; our study family 1 had a baby girl who died at an early age probably due to the similar phenotype. Both the male

![Table 3](image)

| No. | Mutation | Amino acid change | Mutation Type | Reference Authors | Journal (Reference No) |
|-----|----------|-------------------|---------------|--------------------|-----------------------|
| 1   | c.148A > T | Lys50Ter     | Nonsense | Rajab A et al. | Hum Mol Genet 2008 [32] |
| 2   | c.229C > T | Arg77Ter     | Nonsense | Bonfig W et al. | Eur J Pediatr 2011 [5] |
| 3   | c.347A > G | Tyr116Cys | Missense | Netchine I et al. | Nat Genet 2000 [29] |
| 4   | c.368G > A | Cys123Tyr | Missense | Sobrier M et al. | J Clin Endocrinol Metab 2012 [35] |
| 5   | c.437G > T | Cys146Phe | Missense | Ramzan K et al. | BMC Endocr Disord |
| 6   | c.466C > T | Arg156Ter | Nonsense | Ramzan K et al. | BMC Endocr Disord |
| 7   | c.581A > G | Gln194Arg | Missense | Bechtold-Dalla Pozza S et al. | Horm Res Paediatr 2012 [34] |
| 8   | c.644C > T | Ala215Val | Missense | Pfaeffle R et al. | J Clin Endocrinol Metab 2007 [31] |
| 9   | c.687G > A | Trp229Ter | Nonsense | Pfaeffle R et al. | J Clin Endocrinol Metab 2007 [31] |
| 10  | c.267-3C > G | Splicing | Sobrier M et al. | J Clin Endocrinol Metab 2012 [35] |
| 11  | c.470-2 A > G | Splicing | Kristrom B et al. | J Clin Endocrinol Metab 2009 [33] |
| 12  | c.111delT | Gly38Alafs*140 | Deletion | Bhangoo A et al. | J Clin Endocrinol Metab 2006 [30] |
| 13  | c.302-303delG CinsTCTT | Gly101Valfs*78 | Small indel | Pfaeffle R et al. | J Clin Endocrinol Metab 2007 [31] |
| 14  | <14 Mb incl. entire gene | Gross deletion | Pfaeffle R et al. | J Clin Endocrinol Metab 2007 [31] |
| 15  | 23 bp E3I3-3 to E3I3 + 20 | Gross deletion | Netchine I et al. | Nat Genet 2000 [29] |
| 16  | 3088 bp incl. ex. 2-5 | Gross deletion | Rajab A et al. | Hum Mol Genet 2008 [32] |

Nucleotide and amino acid numbering are based on \( LHX3 \), variant 2 (also known as isoform b) and correspond to NCBI reference sequence accession number NM_014564.3 for the cDNA and NP_055379.1 for the protein. Nucleotide numbering commenced with the A of the ATG translation initiation codon as +1
patients had markedly delayed pubertal development and micropenis symptom, which can thus facilitate the diagnosis in case of a male child. Short neck and neonatal hypoglycemia may be overlooked in neonatal cases, but the prolonged jaundice and hypothyroidism should lead to the diagnosis of CPHD.

The incidence of reported mutations in LHX3 gene remains low. Clinical, hormonal and radiological work-up is very important to better determine which transcription factor should be screened. We suggest that the presence of SNHL and limited neck rotation be considered in the differential diagnosis of CPHD3 to facilitate molecular diagnosis. The identification of a LHX3 mutation at an early age is likely to be beneficial for patients to start an appropriate replacement of hormone deficiencies, auditory testing to allow regular speech development, counseling for limitations of cervical mobility and development of scoliosis, and for continual monitoring of these patients. The importance to characterize the patients with CPHD should be emphasized to physicians and researchers to help the genetic screening of patients, and to assist genetic counseling and prenatal diagnosis.

Abbreviations
ACTH: Adrenocorticotrophic hormone; CPHD: Combined pituitary hormone deficiency; FSH: Follicular stimulating hormone; FT4: Free thyroxine; GH: Growth hormone; IGF1: Insulin growth factor 1; IGFBP3: Insulin growth factor binding protein 3; LH: Luteinizing hormone; LIM-HD: LIM-homeodomain; MRI: Magnetic resonance imaging; PRL: Prolactin; SNHL: Sensorineural hearing loss; TSH: Thyroid stimulating hormone; ZNF: Zinc-finger

Acknowledgement
The authors thank patients and their families for their participation. We also thank the sequencing core facilities for their technical help.

Funding
This work was funded and supported in part by King Faisal Specialist Hospital and Research Centre (RAC#85722) and the King Salman Centre for Disability Research (KSCDR #85722).

Availability of data and materials
All data contained within the article.

Authors’ contributions
KR was primarily responsible for the molecular genetic studies, data interpretation, drafting and finalizing the manuscript; BB and MO were primarily responsible for clinical support, clinical evaluation and sample collection; BB and MO also participated in editing of the manuscript; RA assisted in carrying out molecular genetic studies; LA coordinated the study; FI provided oversight for the project and final editing of the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from all the family members for publication of this case report and any accompanying images. Parents provided consent to publish on behalf of all minors. A copy of the written consent is available for review by the Editor of this journal.

Ethics approval and consent to participate
Approval for this study was obtained from the KFSSH & RC ethics committee (RAC#1000.001). All family members gave informed written consent to participate in the genetic test. Parents provided the informed consent for participation of patients 1, 2 and 3 and all other siblings who are minor.

Author details
1Department of Genetics, King Faisal Specialist Hospital and Research Centre, P.O.Box 3354, Riyadh 11211, Saudi Arabia. 2Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 3Department of Medical Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 4College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Received: 7 September 2016 Accepted: 22 February 2017
Published online: 16 March 2017

References
1. Kelberman D, Dattani MT. Hypothalamic and pituitary development: novel insights into the aetiology. Eur J Endocrinol. 2007;157 Suppl 1:13-14.
2. Dacozz D, Romero C, Zunica J, Marshall J, Radovick S. A novel dominant negative mutation of OXT2 associated with combined pituitary hormone deficiency. J Clin Endocrinol Metab. 2009;93:4531-8.
3. Romero C, Pine-Tweddell E, Radovick S. Novel mutations associated with combined pituitary hormone deficiency. J Mol Endocrinol. 2011;46:R93–R102.
4. Kelberman D, Dattani MT. The role of transcription factors implicated in anterior pituitary development in the aetiology of congenital hypopituitarism. Ann Med. 2006;38:560–77.
5. Bonfig W, Krude H, Schmidt H. A novel mutation of LHX3 is associated with combined pituitary hormone deficiency including ACTH deficiency, sensorineural hearing loss, and short neck—a case report and review of the literature. Eur J Pediatr. 2011;170:1017–21.
6. Bach L, Rhodes SJ, Pearse 2nd RV, Heinzel T, Goss B, Scully KM, Sawchenko PE, Rosenfeld MG. P-Lim, a LIM homeodomain factor, is expressed during pituitary organ and cell commitment and synergizes with Pit-1. Proc Natl Acad Sci U S A. 1995;92:2720–4.
7. Sloop KW, Meiier BC, Birdwell JL, Parker GE, Schiffel AM, Rhodes SJ. Differential activation of pituitary hormone genes by human Lhx3 isoforms with distinct DNA binding properties. Mol Endocrinol. 1999;13:2212–25.
8. West BE, Parker GE, Savage JJ, Kiratiparanon P, Toomey KS, Beach LR, Colvin SC, Sloop KW, Rhodes SJ. Regulation of the follicle-stimulating hormone beta gene by the LHX3 LIM-homeodomain transcription factor. Endocrinology. 2004;145:4866–79.
9. Chaudhary V, Bano S. Imaging of pediatric pituitary endocrinopathies. Indian J Endocrinol Metab. 2012;16:662–9.
10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Higde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
11. Venselaar H, De Beek TA, Kuipers RK, Heikkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. BMC Bioinf. 2010;11:548.
12. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda: National Center for Biotechnology Information, National Library of Medicine; (dbSNP Build ID: 129). http://www.ncbi.nlm.nih.gov/SNP/. Accessed 14 Feb 2017.
13. 1000 Genome projects. http://browser.1000genomes.org/. Accessed 14 Feb 2017.
14. Exome Aggregation Consortium (ExAC). http://exac.broadinstitute.org/. Accessed 14 Feb 2017.
15. Bhati M, Lee C, Nancarrow AL, Lee M, Craig VJ, Bach I, Guss JM, Mackay JP, Matthews JM, Bhati M, Lehtomaki E, Mansfield RE, Cubeddu L, Mackay JP. It takes two to tango: the structure and function of LIM, RING, PHD and MYND domains. Curr Pharm Des. 2009;15:3681–96.
16. Perez-Alvarado GC, Miles C, Michelsen JW, Louis HA, Wingre DR, Beckerle MC, Summers MF. Structure of the carboxy-terminal LIM domain from the cysteine rich protein CRP. Nat Struct Biol. 1994;1:388–98.
17. Kadmars J, Beckerle MC. The LIM domains: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 2004;5:920–31.
18. Prince K, Walvoord EC, Rhodes SJ. The role of homeodomain transcription factors in heritable pituitary disease. Nat Rev Endocrinol. 2011;7:227–37.
20. de Moraes DC, Vaisman M, Conceicao FL, Ortega-Carvalho TM. Pituitary development: a complex, temporal regulated process dependent on specific transcriptional factors. J Endocrinol. 2012;215:239–45.

21. Gleiberman AS, Fedtsova NG, Rosenfeld MG. Tissue interactions in the induction of anterior pituitary: role of the ventral diencephalon, mesenchyme, and notochord. Dev Biol. 1999;213:340–53.

22. Dattani MT. Growth hormone deficiency and combined pituitary hormone deficiency: does the genotype matter? Clin Endocrinol (Oxf). 2005;63:121–30.

23. Simons DM, Voss JW, Inghram HA, Holloway JM, Brodie RS, Rosenfeld MG, Swanson LW. Pituitary cell phenotypes involve cell-specific Pit-1 mRNA translation and synergistic interactions with other classes of transcription factors. Genes Dev. 1990;4:695–711.

24. Seidah NG, Barale JC, Marcinikiewicz M, Mattei MG, Day R, Chretien M. The mouse homeoprotein mLIM-3 is expressed early in cells derived from the neuroepithelium and persists in adult pituitary. DNA Cell Biol. 1994;13:1163–80.

25. Sheng HZ, Zhadanov AB, Mosinger Jr B, Fujii T, Bertuzzi S, Grinberg A, Lee EJ, Huang SP, Mahori KA, Westphal H. Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science. 1996;272:1004–7.

26. Tsuchida T, Ennis M, Morton SB, Baldassare M, Edlund T, Jessell TM, Pfaff SL. Topographic organization of embryonic motor neurons defined by expression of LIM homeobox genes. Cell. 1994;79:957–70.

27. Sharma K, Sheng HZ, Lettieri K, Li H, Karavanov A, Potter S, Westphal H, Pfaff SL. LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons. Cell. 1998;95:817–28.

28. The Human Gene Mutation Database, http://www.hgmd.cf.ac.uk. Accessed 14 Feb 2017.

29. Netchine I, Sobrier ML, Krude H, Schnabel D, Maghnie M, Marcos E, Duriez B, Cacheux V, Moers A, Goossens M, Gruters A, Amselem S. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet. 2000;25:182–6.

30. Bhargoo AP, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walcood EC, Ten S, Rhodes SJ. Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency. J Clin Endocrinol Metab. 2006;91:747–53.

31. Pfaffle RW, Savage JJ, Hunter CS, Palme C, Ahlmann M, Kumar P, Bellone J, Schoeneau E, Korsch E, Brämswig JH, Stobbe HM, Blum WF, Rhodes SJ. Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J Clin Endocrinol Metab. 2007;92:1909–19.

32. Rajab A, Kelberman D, de Castro SC, Biebertmann H, Shaikh H, Pearce K, Hall CM, Shaikh G, Guerle A, Krude H, Dattani MT. Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss. Hum Mol Genet. 2008;17:2135–9.

33. Kristrom B, Zdunek AM, Rydh A, Jonsson H, Sehlin P, Escher SA. A novel mutation in the LIM homeobox 3 gene is responsible for combined pituitary hormone deficiency, hearing impairment, and vertebral malformations. J Clin Endocrinol Metab. 2009;94:1154–61.

34. Bechtold-Dalla Pozza S, Hiedl S, Roeb J, Lohse P, Malik RE, Park S, Durán-Prado M, Rhodes SJ. A recessive mutation resulting in a disabling amino acid substitution (T119R) in the LH3 homeodomain causes combined pituitary hormone deficiency. Horm Res Paediatr. 2012;77:41–51.

35. Sobrier ML, Brachet C, Vie-Luton MP, Perez C, Copin B, Legendre M, Heinrichs C, Amselem S. Symptomatic heterozygotes and prenatal diagnoses in a nonconsanguineous family with syndromic combined pituitary hormone deficiency resulting from two novel LHX3 mutations. J Clin Endocrinol Metab. 2012;97:E503–509.